Moleculin Biotech, Inc. 8-K Report: Key Developments on December 18, 2024
Based on the provided section of the financial report, here are the key pieces of information extracted:
- Company Information:
- Name: Moleculin Biotech, Inc.
- Incorporation State: Delaware (DE)
- CIK: 0001659617
- Address: 5300 Memorial Drive, Suite 950, Houston, TX 77007
- Phone Number: 713-300-5160
- SEC Filing Details:
- Filing Type: 8-K
- Filing Date: December 18, 2024
- SEC File Number: 001-37758
- Stock Information:
- Common Stock Ticker Symbol: MBRX
- Exchange: NASDAQ
- Reporting Period:
- Start Date: December 18, 2024
- End Date: December 18, 2024
- The context indicates that this is a specific date reporting rather than a traditional reporting period (e.g., quarterly or annual).
- Namespace Information:
- The document is structured in XBRL (eXtensible Business Reporting Language), indicating it is likely intended for automated financial analysis and reporting.
Insights:
- The filing is a Form 8-K, which typically indicates significant events or changes that shareholders should know about. The specific date suggests that this report may relate to a notable event that occurred on that day.
- The entity is listed on NASDAQ, which may help investors and analysts gauge market activity and stock performance.
- The concise nature of the reporting period (same start and end date) suggests that this filing may be addressing a specific corporate event rather than routine financial disclosures.
This information can be useful for investors, analysts, and stakeholders interested in recent developments related to Moleculin Biotech, Inc.